South Korea’s first domestically developed CAR-T cell therapy, Curonix’s “Anbal-cel” (anbalcabtagene autoleucel), has moved one step closer to national health insurance coverage. The Health Insurance Review and Assessment Service (HIRA) recently reached a decision regarding the reimbursement criteria for the treatment, marking a significant milestone for patients battling specific blood cancers in South Korea.
The development of Rimkato (anbalcabtagene autoleucel) represents a major advancement in the domestic biotechnology sector, as it is the first chimeric antigen receptor T-cell (CAR-T) therapy produced entirely within the country. According to official records from the Health Insurance Review and Assessment Service (HIRA), the agency’s Severe Disease Review Committee evaluated the therapy’s clinical efficacy and cost-effectiveness during its recent deliberation process, setting the stage for potential integration into the national medical insurance system.
Understanding Rimkato and CAR-T Therapy
CAR-T therapy is a sophisticated form of immunotherapy that involves reprogramming a patient’s own T-cells to identify and destroy cancer cells. Rimkato, developed by the South Korean firm Curonix, is specifically designed to treat patients with relapsed or refractory B-cell lymphoma. Because these therapies involve personalized cell manufacturing, they are traditionally associated with high costs, making the transition to national health insurance coverage a vital factor for patient accessibility.
The Ministry of Food and Drug Safety (MFDS) serves as the primary regulatory body overseeing the safety and efficacy standards for such advanced medicinal products. By achieving favorable status within the HIRA review process, Rimkato is positioned to become a more viable treatment option for patients who have previously exhausted standard chemotherapy or stem cell transplant options.
The Path to Reimbursement
The journey toward insurance coverage involves several strictly defined administrative stages. Following the recommendation from the Severe Disease Review Committee, the next steps include price negotiations with the National Health Insurance Service (NHIS). These negotiations determine the final reimbursement price, which must balance the manufacturer’s R&D investment with the financial sustainability of the national health insurance fund.
According to the National Health Insurance Service (NHIS), the negotiation phase is the final hurdle before a drug can be officially listed for insurance benefits. This process ensures that high-cost innovative therapies remain accessible while maintaining the integrity of the public healthcare budget. Stakeholders in the oncology community are closely monitoring these talks, as the availability of a domestic CAR-T option could reduce reliance on imported therapies and lower logistics-related costs.
Impact on Patients and the Domestic Biotech Industry
For patients, the potential inclusion of Rimkato in the insurance system means a substantial reduction in out-of-pocket medical expenses. CAR-T treatments often cost hundreds of millions of won, a financial burden that can be prohibitive for many families. By securing government-backed coverage, the treatment becomes a standard medical service rather than a luxury, significantly increasing the number of patients who can access life-saving immunotherapy.
From an industry perspective, the success of Curonix demonstrates the growing capabilities of the South Korean biopharmaceutical sector. Developing a CAR-T therapy requires advanced clean-room facilities and complex genetic engineering expertise. The progress of Rimkato suggests that the local infrastructure for “living drugs” is reaching a level of maturity that allows for competitive development against global pharmaceutical giants.
Next Steps in the Approval Process
The formal listing of Rimkato for national health insurance coverage remains subject to the completion of price negotiations and subsequent approval by the Health Insurance Policy Deliberation Committee. Once these administrative requirements are met, the Ministry of Health and Welfare will issue a formal notification for the drug to be added to the benefits list.
Patients and healthcare providers looking for the latest updates on coverage dates and eligible patient demographics should monitor the official website of the Ministry of Health and Welfare. As the process moves toward finalization, further announcements regarding the effective date of coverage are expected to be posted through the government’s official gazette. We will continue to track the progress of these negotiations and provide updates as they become available.